Nucleic acid-based assays for the detection of high-risk human papillomavirus: A technical review

Cancer Cytopathology

Volumn 122, Issue 9, 2014, Pages 639-645

  Gibson, Jane S ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

cervical cancer; HPV nucleic acid testing; human papillomavirus; molecular tests

Indexed keywords

COLPOSCOPY; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; INFECTION RISK; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS; CLASSIFICATION; GENETICS; HPV NUCLEIC ACID TESTING; ISOLATION AND PURIFICATION; MOLECULAR TESTS; PAPILLOMA VIRUS; UNITED STATES;

VIRUS DNA; VIRUS RNA;

CERVICAL CANCER; HPV NUCLEIC ACID TESTING; HUMAN PAPILLOMAVIRUS; MOLECULAR TESTS;

DNA, VIRAL; HUMANS; PAPILLOMAVIRIDAE; RNA, VIRAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84908495287     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21451     Document Type: Review

References (22)

1. Davey DD, Goulart R, Nayar R,; Cytopathology Education and Technology Consortium (CETC). 2013 statement on human papillomavirus DNA test utilization. Am J Clin Pathol. 2014; 141: 459-461.
2. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al., The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995; 61: 306-311.
3. Stoler MH, Castle PE, Solomon D, Schiffman M,; American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127: 335-337.
4. Solomon D, Schiffman M, Tarone R,; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93: 293-299.
5. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL,. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012; 206: 46 e41-46e11.
6. Massad LS, Einstein MH, Huh WK, et al, 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013; 121: 829-846.
7. Saslow D, Solomon D, Lawson HW, et al,; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137: 516-542.
8. US Food and Drug Administration. Hybrid Capture 2 High-Risk HPV DNA Test® (hc2) Labeling. accessdata.fda.gov/cdrh-docs/pdf/P890064S009c.pdf. Accessed January 22, 2014.
9. Cox JT,. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol. 2009; 45 (suppl 1): S3-S12.
10. US Food and Drug Administration. Cervista™ HPV HR Labeling. accessdata.fda.gov/cdrh-docs/pdf8/P080014c.pdf. Accessed January 22, 2014.
11. Munson E, Schroeder ER, Ross KC, et al., Effect of preanalytical processing of ThinPrep specimens on detection of high-risk human papillomavirus by the Aptima HPV assay. J Clin Microbiol. 2014; 52: 1448-1452.
12. Moore C, Cuschieri K, McQueen F, Duvall E, Graham C, Cubie HA,. Effect of glacial acetic acid pre-treatment of cervical liquid-based cytology specimens on the molecular detection of human papillomavirus. Cytopathology. 2013; 24: 314-320.
13. McMenamin M, McKenna M,. Stability of human papillomavirus (HPV) in cervical ThinPrep specimens previously lysed with glacial acetic acid: effect on cobas 4800 HPV test performance. Cancer (Cancer Cytopathol). 2014; 122: 250-256.
14. Webber H, Stevens L, Ianosi-Irimie M, et al., High-risk human papillomavirus screening of gynecologic specimens: comparison of the Roche cobas 4800 with the Hologic Cervista assays. Am J Clin Pathol. 2012; 138: A233. ajcp.ascpjournals.org/content/138/Supplement-2/A233.full.pdf. Accessed May 26, 2014.
15. US Food and Drug Administration. Cervista™ HPV 16/18 Labeling. accessdata.fda.gov/cdrh-docs/pdf8/P080015c.pdf. Accessed January 22, 2014.
16. US Food and Drug Administration. cobas® HPV Test Labeling. accessdata.fda.gov/cdrh-docs/pdf10/P100020c.pdf. Accessed January 22, 2014.
17. US Food and Drug Administration. 2014 Meeting Materials of the Microbiology Medical Devices Panel of the Medical Devices Advisory Committee. fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/ucm388531.htm. Accessed March 20, 2014.
18. US Food and Drug Administration. APTIMA® HPV Assay Labeling. accessdata.fda.gov/cdrh-docs/pdf10/P100042c.pdf. Accessed January 22, 2014.
19. US Food and Drug Administration. APTIMA® HPV 16 18/45 Genotype Assay Labeling. accessdata.fda.gov/cdrh-docs/pdf12/P120007c.pdf. Accessed January 22, 2014.
20. Szarewski A, Mesher D, Cadman L, et al., Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012; 50: 1867-1873.
21. Cuzick J, Cadman L, Mesher D, et al., Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013; 108: 908-913.
22. Sauter JL, Mount SL, St John TL, Wojewoda CM, Bryant RJ, Leiman G,. Testing of integrated human papillomavirus mRNA decreases colposcopy referrals: could a change in human papillomavirus detection methodology lead to more cost-effective patient care? Acta Cytol. 2014; 58: 162-166.